Dana-Farber Cancer Institute
Aswin Sekar, MD, PhD

Aswin Sekar, MD, PhD

Medical Oncology
Top Doctor Award Badge
MAKE AN APPOINTMENT

On This Page

Biography

Aswin Sekar, MD, PhD

Dr. Sekar received his MD and PhD from Harvard Medical School.  He then completed his residency training in internal medicine at Brigham and Women's hospital, followed by hematology/oncology fellowship training at Dana-Farber/Mass General Brigham.  His research focuses on pre-cancerous states preceding leukemia and lymphomas, with the ultimate goal of preventing their progression to blood cancers and other adverse clinical outcomes.

Researcher

Physician

Physician, Dana-Farber Cancer Institute
Instructor in Medicine, Harvard Medical School

Centers/Programs

Center for Early Detection and Interception of Blood Cancers
Lymphoma
Center for Chronic Lymphocytic Leukemia (CLL)

Clinical Interests

Chronic Lymphocytic Leukemia (CLL), Monoclonal B-cell lymphocytosis (MBL)

Diseases Treated

Board Certification

  • Hematology, 2024
  • Internal Medicine, 2020

Fellowship

  • Dana-Farber Cancer Institute and Massachusetts General Hospital

Residency

  • Brigham and Women's Hospital, Internal Medicine

Medical School

  • Harvard Medical School

Research Departments

Publications

    View Dr. Sekar's Publications

    • Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. Circ Heart Fail. 2019 11; 12(11):e006214. View in: Pubmed

    • Complement genes contribute sex-biased vulnerability in diverse disorders. Nature. 2020 06; 582(7813):577-581. View in: Pubmed

    • Idelalisib in indolent NHL - has it finally found its niche? Leuk Lymphoma. 2021 05; 62(5):1029-1030. View in: Pubmed

    • Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021 11; 27(11):1921-1927. View in: Pubmed

    • Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J Exp Med. 2021 12 06; 218(12). View in: Pubmed

    • Author Correction: Schizophrenia risk from complex variation of complement component 4. Nature. 2022 Jan; 601(7892):E4-E5. View in: Pubmed

    • TET2-mutant clonal hematopoiesis and risk of gout. Blood. 2022 09 08; 140(10):1094-1103. View in: Pubmed

    • Blood's life history traced through genomic scars. Nature. 2022 06; 606(7913):255-256. View in: Pubmed

    • Association of Somatic TET2 Mutations With Giant Cell Arteritis. Arthritis Rheumatol. 2024 Mar; 76(3):438-443. View in: Pubmed

    • JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism. Blood. 2024 Nov 14; 144(20):2149-2154. View in: Pubmed

    • Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia. Blood Adv. 2024 Dec 10; 8(23):5949-5956. View in: Pubmed

    • Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL). Blood Cancer J. 2024 11 06; 14(1):193. View in: Pubmed

    • Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia. Blood Adv. 2025 Jun 10; 9(11):2808-2817. View in: Pubmed

    • Identification of genetic variants using bar-coded multiplexed sequencing. Nat Methods. 2008 Oct; 5(10):887-93. View in: Pubmed

    • Schizophrenia risk from complex variation of complement component 4. Nature. 2016 Feb 11; 530(7589):177-83. View in: Pubmed

    • Fine mapping of regulatory loci for mammalian gene expression using radiation hybrids. Nat Genet. 2008 Apr; 40(4):421-9. View in: Pubmed

    • Identification of somatic chromosomal abnormalities in hypothalamic hamartoma tissue at the GLI3 locus. Am J Hum Genet. 2008 Feb; 82(2):366-74. View in: Pubmed

    Locations

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1083

    Ratings and Comments

    Aswin Sekar, MD, PhD

    About Our Ratings

    Physician Star Rating Comment Block

    Discovery and Insights

    Back to Top